D Garcia-Borreguero

Summary

Affiliation: Sleep Research Institute
Country: Spain

Publications

  1. ncbi Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Mov Disord 27:277-83. 2012
  2. ncbi Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
    Birgit Hogl
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    BMC Neurol 10:86. 2010
  3. ncbi Time to REST: epidemiology and burden
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 13:15-20. 2006
  4. ncbi Management of restless legs syndrome augmentation
    Anne Marie Williams
    Diego Garcia Borreguero, MD, PhD, Sleep Research Institute, 19 Alberto Alcocer, 28036 Madrid, Spain
    Curr Treat Options Neurol 11:327-32. 2009
  5. ncbi Dopaminergic augmentation of restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, Madrid, Spain
    Sleep Med Rev 14:339-46. 2010
  6. ncbi Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study
    D Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Neurology 74:1897-904. 2010
  7. ncbi A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:742-52. 2007
  8. ncbi Augmentation as a treatment complication of restless legs syndrome: concept and management
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Mov Disord 22:S476-84. 2007
  9. ncbi Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med 8:119-27. 2007
  10. ncbi Epidemiology of restless legs syndrome: the current status
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med Rev 10:153-67. 2006

Detail Information

Publications30

  1. ncbi Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Mov Disord 27:277-83. 2012
    ..The incidence of augmentation was 3.1% higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study...
  2. ncbi Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
    Birgit Hogl
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    BMC Neurol 10:86. 2010
    ..This study reports the 2-year follow-up safety and efficacy data of an ongoing open-label multicenter extension study (NCT00498186) of transdermal rotigotine in patients with moderate to severe restless legs syndrome (RLS)...
  3. ncbi Time to REST: epidemiology and burden
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 13:15-20. 2006
    ..Given the significant burden of morbidity associated with RLS, there is a strong case for treatment in patients with troublesome symptoms...
  4. ncbi Management of restless legs syndrome augmentation
    Anne Marie Williams
    Diego Garcia Borreguero, MD, PhD, Sleep Research Institute, 19 Alberto Alcocer, 28036 Madrid, Spain
    Curr Treat Options Neurol 11:327-32. 2009
    ....
  5. ncbi Dopaminergic augmentation of restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, Madrid, Spain
    Sleep Med Rev 14:339-46. 2010
    ..RLS is treated by maintaining low doses of dopaminergic agents and ensuring iron sufficiency. Non-dopaminergics and opiates can be used when patients experience augmentation with more than one dopaminergic agent...
  6. ncbi Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study
    D Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Neurology 74:1897-904. 2010
    ..To assess the therapeutic efficacy, required dose, and tolerability of pregabalin in patients with idiopathic restless legs syndrome (RLS)...
  7. ncbi A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:742-52. 2007
    ..To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks...
  8. ncbi Augmentation as a treatment complication of restless legs syndrome: concept and management
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Mov Disord 22:S476-84. 2007
    ..The present article reviews our current knowledge on clinical diagnosis, evaluation, pathophysiology, and treatment recommendations for this condition...
  9. ncbi Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med 8:119-27. 2007
    ..To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS)...
  10. ncbi Epidemiology of restless legs syndrome: the current status
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med Rev 10:153-67. 2006
    ..In summary, epidemiological evidence suggests that RLS is a common neurological disorder-with high impact on many aspects of the life of those affected...
  11. ncbi Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome
    Diego Garcia-Borreguero
    Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med 8:455-63. 2007
    ..The changes in each dimension are summed to give an ASRS total score...
  12. ncbi Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:520-30. 2007
    ..The Consensus Conference sought to develop a better understanding of augmentation and generate a better operational definition for its clinical identification...
  13. ncbi Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease)
    D Tzonova
    Sleep Research Institute, Madrid, Spain
    Sleep Med 13:151-5. 2012
    ..However, previous studies have estimated the prevalence of daytime symptoms to be 10-60%. This study sought to investigate the prevalence and pattern of daytime symptoms in patients with moderate-to-severe RLS...
  14. ncbi L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment
    D Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
    Neurology 61:1008-10. 2003
    ..Mean sleep latency with L-dopa was 7 minutes, in contrast to a normal value of 19 minutes, 25 seconds with placebo. The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease...
  15. ncbi Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study
    D Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Neurology 59:1573-9. 2002
    ..To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)...
  16. ncbi Restless legs syndrome: an overview of the current understanding and management
    D Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Acta Neurol Scand 109:303-17. 2004
    ..In conclusion, these and other recent findings shed light on our understanding and management of one of the most common movement disorders...
  17. ncbi The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting
    Linda Abetz
    Mapi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UK
    Sleep Med 7:340-9. 2006
    ..0), using pooled data from two matching, placebo-controlled studies of ropinirole for treating Restless Legs Syndrome (RLS)...
  18. ncbi Restless legs syndrome and PD: a review of the evidence for a possible association
    Diego Garcia-Borreguero
    Department of Neurology, , , Madrid, Spain
    Neurology 61:S49-55. 2003
    ..Therefore, neuronal degeneration in other dopaminergic pathways than the nigrostriatal might be relevant in the pathogenesis of RLS in PD...
  19. ncbi Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep 27:669-73. 2004
    ....
  20. ncbi Correlation between rating scales and sleep laboratory measurements in restless legs syndrome
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Avda Reyes Catolicos 2, Madrid 28040, Spain
    Sleep Med 5:561-5. 2004
    ....
  21. ncbi Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Mov Disord 17:934-41. 2002
    ..Potential implications for the understanding of the relationship between RBD and PD are discussed...
  22. ncbi Circadian effects of dopaminergic treatment in restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Disorders Unit, Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Avda Reyes Catolicos 2, 28040 Madrid, Spain
    Sleep Med 5:413-20. 2004
    ..The reverse is also possible; dopaminergic medication might affect melatonin function, a key element of the circadian system. The present study investigated the effects of dopaminergic medication on melatonin secretion in RLS...
  23. ncbi Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe
    Wolfgang H Oertel
    Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, D 35039 Marburg, Germany
    Sleep Med 9:228-39. 2008
    ..In a pilot placebo-controlled study, low dosages of 0.5-2mg/24h rotigotine showed a dose-dependent beneficial effect in restless legs syndrome (RLS) patients...
  24. ncbi Augmentation: understanding a key feature of RLS
    Diego Garcia-Borreguero
    Sleep Med 5:5-6. 2004
  25. ncbi Parkinson's disease and sleep
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med Rev 7:115-29. 2003
    ..An adequate education of the PD patients in sleep hygiene measures and a skilled use of the medication seem necessary to prevent sleep disturbance...
  26. ncbi The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Grou
    Marco Zucconi
    Sleep Disorders Center, San Raffaele Hospital, Milano, Italy
    Sleep Med 7:175-83. 2006
  27. ncbi Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Lancet Neurol 7:595-604. 2008
    ..Continuous administration of a dopamine agonist could be used to treat patients with restless legs syndrome. Our aim was to investigate the efficacy of transdermal rotigotine in the treatment of idiopathic restless legs syndrome...
  28. ncbi Assessment of restless legs syndrome--methodological approaches for use in practice and clinical trials
    Ralf Kohnen
    IMEREM Institute for Medical Research Management, Biometrics Ltd, University of Erlangen Nuremberg, Nuremberg, Germany
    Mov Disord 22:S485-94. 2007
    ....
  29. ncbi Tireless work on restless legs: guest editors' introduction
    Claudia Trenkwalder
    Paracelsus-Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr. 16, 34128 Kassel, Germany
    Mov Disord 22:S393-4. 2007
  30. ncbi Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG)
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Mov Disord 22:S495-504. 2007
    ..The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols...